Astria Therapeutics (NASDAQ:ATXS) Rating Reiterated by Wedbush

Wedbush reissued their outperform rating on shares of Astria Therapeutics (NASDAQ:ATXS) in a research report sent to investors on Tuesday, Benzinga reports. Wedbush currently has a $17.00 price objective on the biotechnology company’s stock.

Several other equities research analysts also recently issued reports on ATXS. Jefferies Financial Group raised their target price on shares of Astria Therapeutics from $22.00 to $27.00 and gave the company a buy rating in a research note on Monday, March 25th. HC Wainwright restated a buy rating and set a $18.00 price objective on shares of Astria Therapeutics in a research report on Monday, March 25th.

Astria Therapeutics Stock Performance

Shares of NASDAQ:ATXS opened at $14.08 on Tuesday. Astria Therapeutics has a 52-week low of $4.26 and a 52-week high of $16.90. The company has a market capitalization of $772.72 million, a P/E ratio of -6.01 and a beta of 0.72. The company has a 50-day simple moving average of $13.80 and a 200 day simple moving average of $8.83.

Astria Therapeutics (NASDAQ:ATXS) last issued its earnings results on Monday, March 4th. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($0.08). As a group, equities analysts forecast that Astria Therapeutics will post -1.55 earnings per share for the current year.

Insider Activity

In other Astria Therapeutics news, Director Perceptive Advisors Llc purchased 2,481,350 shares of the company’s stock in a transaction dated Thursday, February 1st. The stock was bought at an average cost of $12.09 per share, for a total transaction of $29,999,521.50. Following the completion of the transaction, the director now owns 4,873,721 shares in the company, valued at $58,923,286.89. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Christopher Morabito sold 9,200 shares of Astria Therapeutics stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $11.15, for a total value of $102,580.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Perceptive Advisors Llc acquired 2,481,350 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The stock was purchased at an average cost of $12.09 per share, for a total transaction of $29,999,521.50. Following the completion of the purchase, the director now directly owns 4,873,721 shares of the company’s stock, valued at $58,923,286.89. The disclosure for this purchase can be found here. 3.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ATXS. Tower Research Capital LLC TRC increased its stake in Astria Therapeutics by 416.5% in the third quarter. Tower Research Capital LLC TRC now owns 3,357 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 2,707 shares during the last quarter. Legal & General Group Plc grew its stake in shares of Astria Therapeutics by 34.4% during the fourth quarter. Legal & General Group Plc now owns 3,492 shares of the biotechnology company’s stock worth $27,000 after buying an additional 894 shares during the last quarter. UBS Group AG grew its stake in shares of Astria Therapeutics by 12,948.0% during the third quarter. UBS Group AG now owns 3,262 shares of the biotechnology company’s stock worth $29,000 after buying an additional 3,237 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Astria Therapeutics during the second quarter worth $41,000. Finally, AJOVista LLC bought a new stake in shares of Astria Therapeutics during the fourth quarter worth $51,000. 98.98% of the stock is owned by institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.